Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Used to Diagnose Polycystic Ovary Syndrome

By LabMedica International staff writers
Posted on 30 Jun 2017
An enzyme-linked immunosorbent assay (ELISA) has been developed to detect autoantibodies in polycystic ovary syndrome (PCOS), a method that could pave the way for a quicker, more efficient way to diagnose this elusive condition, where the etiology is unclear.

Medical scientists at the University of Oklahoma (Norman, OK, USA) analyzed the serum of 32 patients with PCOS based on Rotterdam criteria and 38 age and body mass index (BMI) matched, ovulatory infertile women. These included seven diagnosed with Tubal Factor (TF), 12 Male Factor (MFI), and 19 unexplained infertile women. The team hypothesized that activating autoantibodies directed to the second extracellular loop (ECL2) of the gonadotropin releasing hormone receptor (GnRHR) could be present in PCOS patients and possibly be pathogenic and of diagnostic value. Such antibodies to other G protein receptors have been found to be significant in many disorders affecting predominantly women.

The scientists identified and synthesized the 28 AA hGnRHR ECL2 loop and used this epitope target for an ELISA assay. They found a significant increase in the developed ELISA optical density in subjects with PCOS (0.26±0.07) compared to subjects with TF (0.20±0.05), subjects with MFI (0.17±0.03), and subjects with unexplained infertility (0.17±0.03). These differences were maintained regardless of the BMI. This assay demonstrated a sensitivity of 91% and a specificity of 87% for PCOS.

The authors concluded that this autoantibody targeting the second ECL of the GnRHR at the hypothalamic/pituitary level will likely be causative of the abnormal cycling shown by PCOS subjects. The present assay, with validation from their ongoing activity and blocking studies, may represent the desired serological test needed to effectively screen subjects for possible PCOS.

David C. Kem, MD, the senior investigator, said, “We’d noticed that several female patients with postural orthostatic tachycardia syndrome (POTS) had autoantibodies that activate specific receptors called G-protein coupled receptors. It dawned on me that this type of autoantibody might also be present in PCOS patients, and the likely target for that would be receptors in the pituitary gland. We noticed in the course of our work that the autoantibodies connected to these receptors were using the second extracellular loop, a part of the receptor that sticks out from the cell wall into the serum.” The study was presented at the American Association of Clinical Endocrinologists’ 26th Annual Scientific & Clinical Congress held May 3-7, 2017, in Austin, Texas.

Related Links:
University of Oklahoma


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Troponin I Test
Quidel Triage Troponin I Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.